These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27515717)

  • 1. The Added Prognostic Value of Metabolic Tumor Size on FDG-PET at First Suspected Recurrence of Glioblastoma Multiforme.
    Chiang GC; Galla N; Ferraro R; Kovanlikaya I
    J Neuroimaging; 2017 Mar; 27(2):243-247. PubMed ID: 27515717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
    Tralins KS; Douglas JG; Stelzer KJ; Mankoff DA; Silbergeld DL; Rostomily RC; Hummel S; Scharnhorst J; Krohn KA; Spence AM
    J Nucl Med; 2002 Dec; 43(12):1667-73. PubMed ID: 12468518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG PET/MR Imaging Coregistration Helps Predict Survival in Patients with Glioblastoma and Radiologic Progression after Standard of Care Treatment.
    Leiva-Salinas C; Schiff D; Flors L; Patrie JT; Rehm PK
    Radiology; 2017 May; 283(2):508-514. PubMed ID: 28234553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme.
    Pötzi C; Becherer A; Marosi C; Karanikas G; Szabo M; Dudczak R; Kletter K; Asenbaum S
    J Neurooncol; 2007 Sep; 84(3):305-14. PubMed ID: 17492401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer.
    Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ
    J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
    Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
    Baba S; Isoda T; Maruoka Y; Kitamura Y; Sasaki M; Yoshida T; Honda H
    J Nucl Med; 2014 May; 55(5):736-42. PubMed ID: 24665089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
    Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
    J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
    Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
    Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
    Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
    Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
    J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.
    Ng SH; Lin CY; Chan SC; Lin YC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Chang CJ; Wang JJ
    PLoS One; 2014; 9(12):e115933. PubMed ID: 25531391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
    Van Laere K; Ceyssens S; Van Calenbergh F; de Groot T; Menten J; Flamen P; Bormans G; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):39-51. PubMed ID: 15309329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study.
    Harat M; Małkowski B; Makarewicz R
    Radiother Oncol; 2016 Aug; 120(2):241-7. PubMed ID: 27378734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.